CSIMarket
 


Pasithea Therapeutics Corp   (KTTA)
Other Ticker:  
 

Pasithea Therapeutics 's Tangible Leverage Ratio

KTTA's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -11.01%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.1 is above the company's typical Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 31 other companies have achieved lower Tangible Leverage Ratio than Pasithea Therapeutics in the III Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the third quarter 2023 to 81, from total ranking in the second quarter 2023 at 105 .

Explain Tangible Leverage Ratio?
What is KTTA Market Share?
What are KTTA´s Total Liabilities?


KTTA Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -55.71 % -45.28 % -41.06 % -36.51 % 160.53 %
Y / Y Total Liabilities Change -32.66 % 37.28 % 121.98 % -7.64 % -38.27 %
Tangible Leverage Ratio MRQ 0.1 0.08 0.08 0.05 0.07
KTTA's Total Ranking # 81 # 105 # 112 # 39 # 123
Seq. Tangible Equity Change -27.08 % -11.5 % -9.77 % -23.94 % -9.9 %
Seq. Total Liabilities Change -11.01 % -12.72 % 39.28 % -37.76 % 81.42 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 46
Overall Market # 81


Tangible Leverage Ratio Statistics
High Average Low
0.28 0.07 0.02
(Sep 30 2021)   (Mar 31 2022)




Financial Statements
Pasithea Therapeutics 's Tangible Equity $ 19 Millions Visit KTTA's Balance sheet
Pasithea Therapeutics 's Total Liabilities $ 2 Millions Visit KTTA's Balance sheet
Source of KTTA's Sales Visit KTTA's Sales by Geography


Cumulative Pasithea Therapeutics 's Tangible Leverage Ratio

KTTA's Tangible Leverage Ratio for the trailling 12 Months

KTTA Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -55.71 % -45.28 % -41.06 % -36.51 % 160.53 %
Y / Y Total Liabilities TTM Growth -32.66 % 37.28 % 121.98 % -7.64 % -38.27 %
Tangible Leverage Ratio TTM 0.08 0.07 0.06 0.04 0.04
Total Ranking TTM # 2 # 1 # 2 # 30 # 47
Seq. Tangible Equity TTM Growth -27.08 % -11.5 % -9.77 % -23.94 % -9.9 %
Seq. Total Liabilities TTM Growth -11.01 % -12.72 % 39.28 % -37.76 % 81.42 %


On the trailing twelve months basis Despite of the repayements of liabilities of -11.01% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.08, above Pasithea Therapeutics 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry KTTA recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 1 to 2.

Explain Tangible Leverage Ratio?
What is KTTA Market Share?
What are KTTA´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 2


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.07 0.06 0.04
(Sep 30 2023)   (Sep 30 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Sunshine Biopharma Inc   0.27 $ 5.687  Millions$ 20.747  Millions
Neurobo Pharmaceuticals Inc   0.27 $ 5.784  Millions$ 21.550  Millions
Imunon Inc   0.27 $ 4.846  Millions$ 18.072  Millions
Cara Therapeutics inc   0.26 $ 22.384  Millions$ 85.642  Millions
Lianbio  0.26 $ 60.564  Millions$ 236.112  Millions
Merus N v   0.25 $ 98.798  Millions$ 391.617  Millions
Regeneron Pharmaceuticals Inc   0.25 $ 5,996.300  Millions$ 23,887.200  Millions
Context Therapeutics Inc   0.25 $ 4.604  Millions$ 18.385  Millions
Bellerophon Therapeutics inc  0.25 $ 0.920  Millions$ 3.723  Millions
Savara Inc   0.24 $ 35.528  Millions$ 146.544  Millions
Assembly Biosciences Inc   0.24 $ 9.915  Millions$ 41.714  Millions
Erasca Inc   0.24 $ 80.431  Millions$ 338.975  Millions
Deciphera Pharmaceuticals Inc   0.23 $ 89.458  Millions$ 381.670  Millions
Calcimedica Inc   0.23 $ 2.826  Millions$ 12.159  Millions
Mei Pharma Inc   0.23 $ 18.835  Millions$ 81.361  Millions
Praxis Precision Medicines Inc   0.23 $ 19.969  Millions$ 86.756  Millions
Repare Therapeutics Inc   0.23 $ 53.039  Millions$ 233.368  Millions
Adial Pharmaceuticals Inc   0.23 $ 0.528  Millions$ 2.335  Millions
United Therapeutics Corporation  0.22 $ 1,270.900  Millions$ 5,667.700  Millions
Frequency Therapeutics Inc   0.22 $ 8.185  Millions$ 36.737  Millions
Ovid Therapeutics Inc   0.22 $ 22.512  Millions$ 101.292  Millions
Procyon Corporation  0.22 $ 0.568  Millions$ 2.578  Millions
Aurinia Pharmaceuticals Inc   0.22 $ 84.230  Millions$ 386.616  Millions
Zentalis Pharmaceuticals Inc   0.22 $ 103.947  Millions$ 478.161  Millions
Benitec Biopharma Inc   0.21 $ 4.745  Millions$ 22.308  Millions
Schrodinger Inc   0.21 $ 117.847  Millions$ 558.790  Millions
Synlogic Inc   0.21 $ 9.144  Millions$ 43.404  Millions
Prothena Corporation Public Limited Company  0.21 $ 129.693  Millions$ 617.227  Millions
Kiniksa Pharmaceuticals ltd   0.20 $ 77.936  Millions$ 387.627  Millions
Adicet Bio Inc   0.20 $ 38.580  Millions$ 194.677  Millions

Date modified: 2024-01-10T05:56:43+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com